Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid
Open Access
- 1 September 2016
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 123 (9) , 1856-1864
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend ProtocolOphthalmology, 2015
- Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized TrialOphthalmology, 2013
- Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trialThe Lancet, 2013
- Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments TrialsOphthalmology, 2013
- A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degenerationBritish Journal of Ophthalmology, 2013
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular DegenerationOphthalmology, 2012
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011